Trial of Melanoma Triplet Combo Raises Questions

Source: Targeted Oncology, June 2017

A 3-drug regimen for advanced melanoma led to objective responses in a majority of patients with advanced BRAF-mutant disease but also proved to be somewhat toxic, a small phase II study showed.1

Results showed that 22 of 42 patients (52.4%) had complete or partial responses when treated with the BRAF inhibitor encorafenib, the MET inhibitor binimetinib, and the CDK4/6 inhibitor ribociclib (Kisqali). The disease control rate (DCR; objective response plus stable disease) was 88%, and the cohort had an estimated progression-free survival (PFS) of 9.2 months (95% CI, 7.0-11.1).

One-fourth of patients discontinued the trial because of adverse events (AEs), most often because of elevated liver enzymes, as reported at the 2017 American Society of Clinical Oncology meeting in Chicago.

read the original full article

Melanoma Google Alerts

Melanoma Google Alerts is a summary of daily articles found in print and on the internet. The articles do not necessarily represent the views of Melbourne Melanoma Project

News Archives

News Categories